

April 30, 2019



# OPKO Health to Report First Quarter 2019 Financial Results on May 7, 2019

MIAMI, April 30, 2019 (GLOBE NEWSWIRE) -- **OPKO Health, Inc.** (NASDAQ: OPK) plans to report its operating and financial results for the three months ended March 31, 2019, as well as provide guidance on expected revenues and operating expenses for the second quarter 2019, after the close of the U.S. financial markets on Tuesday, May 7, 2019.

OPKO's senior management will provide a business update and discuss its financial results in a live conference call and audio webcast beginning at 4:30 p.m. Eastern time on Tuesday, May 7, 2019.

## CONFERENCE CALL & WEBCAST INFORMATION

OPKO's senior management will provide a business update and discuss results in greater detail in a conference call and live audio webcast at 4:30 p.m. Eastern time on Tuesday, May 7, 2019. The conference call dial-in and webcast information is as follows:

DOMESTIC  
DIAL-IN: 866-634-2258  
INTERNATIONAL  
DIAL-IN: 330-863-3454  
PASSCODE: 1547027  
WEBCAST: <https://edge.media-server.com/m6/p/hhtmqq9>

For those unable to participate in the live conference call or webcast, a replay will be available beginning approximately two hours after the close of the conference call. To access the replay, dial 855-859-2056 or 404-537-3406. The replay passcode is 1547027. The replay can be accessed for a period of time on OPKO's website at <https://edge.media-server.com/m6/p/hhtmqq9>

## About OPKO Health, Inc.

OPKO Health is a diversified healthcare company. In diagnostics, its BioReference Laboratories is the nation's third largest clinical laboratory; GeneDx is a rapidly growing genetic testing business; the 4Kscore® prostate cancer test is used to confirm an elevated PSA to help decide about next steps such as prostate biopsy; Claros® 1 is a point-of-care diagnostics platform with a total PSA test approved by the FDA and testosterone as the most advanced test in development. In our pharmaceutical pipeline, RAYALDEE is our first pharmaceutical product to be marketed. OPK88003, a once-weekly oxyntomodulin for type 2 diabetes and obesity recently reported positive data from a Phase 2 clinical trial. It's among a new class of GLP-1/glucagon receptor dual agonists. OPK88004, a SARM (selective androgen receptor modulator) is currently being studied for various potential indications. The Company's most advanced product utilizing its CTP technology, a once-weekly human growth hormone for injection, is in Phase 3 trials, and is partnered with

Pfizer. OPKO also has research, development, production and distribution facilities abroad. More information is available at [www.opko.com](http://www.opko.com).

## **CONTACTS:**

### **Investors**

LHA Investor Relations

Miriam Weber Miller, 212-838-3777

[MMiller@lhai.com](mailto:MMiller@lhai.com)

or

Bruce Voss, 310-691-7100

[bvoss@lhai.com](mailto:bvoss@lhai.com)



Source: OPKO Health, Inc.